FDA Approves Expanded Label of Novartis’ Prostate Cancer Treatment, Pluvicto Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer.

Big news in prostate cancer treatment! The #FDA has expanded the label for Novartis #Pluvicto, now approved before chemotherapy for PSMA-positive metastatic castration-resistant prostate cancer. #TCSC #cancerresearch #prostatecancer #psmafore

www.appliedclinicaltrialsonline.com/view/fda-app...

Intriguing CT DNA presented by Dr. Johann DeBono suggesting the value in assessing treatment response #PSMAfore #Lu-psma #mCRPC #ProstateCancer

Especially appreciate comparison to PSA50 responses given it’s already in clinic

It does make me wonder - what if we looked at PSA80? #GU25

Dr. Louise Emmett presents OS data from #Enzalutamide +/- #Lu-psma in 1st line mCRPC #ProstateCancer

Intriguing data to be sure but would have appreciated a built in cross-over given equivalent OS seen in #PSMAfore in 2nd line mCRPC when ARPI before or after Lu-psma #GU25 @ascocancer.bsky.social